At Legacy Dermatology, our team specializes in precise evaluation of congenital, atypical, and acquired moles, ensuring early detection of potential malignancy and optimal cosmetic outcomes.
Congenital moles, present at birth, vary in size and pigmentation, with large or giant variants carrying elevated melanoma risk. Atypical moles (dysplastic nevi) are irregular in shape, uneven in color, and often familial, requiring close monitoring to prevent malignant transformation.
Acquired moles develop over time, generally benign, but patients with high mole counts or significant color variation are evaluated for preventive interventions.
Our advanced diagnostic approach includes dermatoscopic imaging, digital mole mapping, and ABCDE risk assessment (Asymmetry, Border, Color, Diameter, Evolution) to detect subtle changes indicative of melanoma.
Cosmetic or medically necessary mole removal is performed using state-of-the-art shave excision for small, superficial lesions or precise excisional surgery for deeper or potentially malignant tissue, minimizing scarring and maximizing patient comfort.
Laser-assisted treatments may be integrated for select lesions to enhance aesthetic outcomes. Contact us to discover more advanced mole management strategies and personalized treatments.
Detecting malignant transformation early and accurately
Providing safe, minimally invasive mole removal
Continuous digital mapping for long-term protection
Yes. Shave excision or laser ablation removes superficial lesions with minimal scarring while preserving surrounding skin integrity, supervised by experienced dermatologists.
Congenital moles are present at birth and may carry a higher melanoma risk; acquired moles develop later, are mostly benign, and require ongoing monitoring for irregular changes.
Dysplastic nevi exhibit irregular shapes, uneven pigmentation, and familial inheritance, significantly increasing melanoma risk compared to typical moles, necessitating advanced monitoring strategies.
Patients with atypical or multiple moles should have semiannual digital mapping and dermatoscopic evaluations; low-risk patients should undergo annual clinical assessments.